Marien Hospital Witten
- Address
- Marienplatz 2, 58452 Witten, Germany
Neoplasms and Breast Cancer Research
At Marien Hospital Witten, most trials focus on neoplasms, especially breast cancer in early, locally advanced, and metastatic settings. The research is centered on testing new treatment approaches and improving disease control, with a strong emphasis on survival outcomes and recurrence prevention.
- Studies in ER+/HER2- early breast cancer, HER2-positive breast cancer, and triple-negative breast cancer
- Research in metastatic breast cancer and patients with high risk of recurrence
- Trials evaluating whether newer therapies improve invasive disease-free survival, event-free survival, and pathologic complete response
This broad program reflects a strong effort to refine breast cancer treatment, including options for hormone receptor-positive, HER2-low, and high-risk disease.
Digestive System Cancer Studies
The site also conducts research in digestive system diseases, with trials involving colon cancer, rectal cancer, colorectal cancer, and gastric cancer. These studies are designed to improve treatment effectiveness before or after surgery and to better guide care for patients with localized or metastatic disease.
- Investigations in colon cancer stage II and more advanced colon tumors
- Research in metastatic colorectal cancer and rectal cancer
- Trials exploring whether treatment strategies can improve disease-free survival and progression-free survival
The focus at Brustzentrum includes evaluating new treatment strategies that may help reduce recurrence and improve long-term outcomes in gastrointestinal cancers.
Hormonal Disease and Endocrine-Related Research
A smaller but important part of the research portfolio addresses hormonal diseases, especially symptoms and treatment effects linked to breast cancer care. These trials aim to improve quality of life and optimize endocrine-based treatment for patients with hormone-sensitive disease.
- Studies in hormone receptor-positive breast cancer and endocrine-responsive early breast cancer
- Research on vasomotor symptoms associated with adjuvant endocrine therapy
- Trials testing whether endocrine-based combinations can better prevent recurrence and support treatment effectiveness
Overall, the work combines cancer control with symptom management, reflecting a patient-centered approach to endocrine therapy and long-term care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 55 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 55 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 11 by active trials.
lock +10 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Marien Hospital Witten
lock Showing 1 of 24 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2, randomized, multicenter, open-label neoadjuvant study evaluating zanidatamab in combination with chemotherapy in participants with HER2-positive breast cancer | Jazz Pharmaceuticals Ireland Limited | Phase II | Not Yet Recruiting | Mar 2026 | — |
IMP list
lock Showing 1 of 55 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Paclitaxel | 5 | Unknown | 2018-06-13 | 2026-03-25 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.